Business Context and Reporting Period
This Form 6-K filing by Novo Nordisk A/S, dated August 12, 2024, discloses insider trading activity in compliance with Article 19 of Regulation No. 596/2014 on market abuse. The company is a global healthcare leader headquartered in Denmark, employing approximately 69,000 people across 80 countries.
Key Financial Metrics
The filing text does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document is strictly a regulatory disclosure of a specific share transaction.
| Transaction Detail | Value |
|---|---|
| Instrument | Novo Nordisk B Shares (DK0062498333) |
| Transaction Type | Purchase |
| Volume | 11 Shares |
| Price per Share | DKK 891.20 |
| Total Value | DKK 9,803.20 |
| Date of Transaction | August 9, 2024 |
| Exchange | Nasdaq Copenhagen |
Material Changes
The filing text does not provide information regarding material changes in financial performance or operations compared to prior periods.
Guidance, Outlook, and Risks
The filing text does not contain management guidance, future outlook, risk factors, or contingencies. It includes a standard corporate description stating the company's purpose is to defeat serious chronic diseases, built upon its heritage in diabetes.
Investor Verification Checklist
- Verify the identity of the transacting party: Mathilde Rantzau, identified as a person closely associated with Thomas Rantzau, a member of the Board of Directors.
- Confirm the transaction date (August 9, 2024) and the specific exchange (Nasdaq Copenhagen).
- Note that the transaction volume (11 shares) is nominal and does not indicate a significant change in insider ownership.
- Refer to the company's Form 20-F or quarterly reports for actual financial performance metrics, as they are absent in this filing.